Skip to main content

Abuse, PTSD & Trauma

A meta-analysis recently published in The Lancet Psychiatry found that using medicinal cannabinoids to treat mental health disorders cannot be justified, due to a lack of evidence of effectiveness and known risks of the substances.
An international genome-wide association study of 200,000 people has established that the risk of post-traumatic stress disorder (PTSD) is heritable, silencing theories that the disorder is solely a social construct.
SAN DIEGO—Signs point to possible approval of MDMA-assisted psychotherapy for post-traumatic stress disorder by late 2021, with Rick Doblin, PhD, telling Psych Congress attendees that this could mark the start of a new field of therapy.
A drug that increases levels of a key endocannabinoid in the brain may be useful for helping patients with post-traumatic stress disorder (PTSD) unlearn fear, suggests an early-stage study published online in Biological Psychiatry.
Intergenerational and transgenerational trauma are challenges that require practitioners to dig deeper in their assessments beyond just the presenting patient and his/her nuclear family, says Alex Ribbentrop, MSW, LCSW, CFTP, owner and psychotherapist at Live Free Psychotherapy.
Back to Top